Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INSP Inspire Medical Systems	$126.94 -0.8%	$136.73	$123.00 ▼ $225.00	$3.74B	1.25	559,045 shs	406,188 shs
SLNO Soleno Therapeutics	$87.20 -0.5%	$79.60	$41.50 ▼ $90.32	$4.39B	-2.63	851,184 shs	1.19 million shs
TMDX TransMedics Group	$109.88 -2.3%	$127.16	$55.00 ▼ $177.37	$3.72B	2.06	1.38 million shs	789,501 shs
TNDM Tandem Diabetes Care	$14.77 -3.8%	$19.78	$14.67 ▼ $47.60	$983.83M	1.48	1.50 million shs	1.68 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INSP Inspire Medical Systems	+0.63%	-7.94%	+0.86%	-14.77%	-11.90%
SLNO Soleno Therapeutics	+2.48%	+9.11%	+12.94%	+25.24%	+80.03%
TMDX TransMedics Group	-0.71%	-9.83%	-17.39%	+27.52%	-24.60%
TNDM Tandem Diabetes Care	-2.48%	-5.01%	-23.47%	-8.90%	-66.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
INSP Inspire Medical Systems	4.8691 of 5 stars	4.4	2.0	4.8	2.9	2.5	1.9
SLNO Soleno Therapeutics	4.1837 of 5 stars	3.5	1.0	4.6	2.7	2.5	0.6
TMDX TransMedics Group	2.0926 of 5 stars	2.4	1.0	0.0	2.2	2.5	1.9
TNDM Tandem Diabetes Care	4.3223 of 5 stars	4.2	1.0	4.9	4.1	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INSP Inspire Medical Systems	2.73	Moderate Buy	$210.27	65.65% Upside
SLNO Soleno Therapeutics	3.09	Buy	$108.70	24.66% Upside
TMDX TransMedics Group	2.89	Moderate Buy	$129.88	18.20% Upside
TNDM Tandem Diabetes Care	2.33	Hold	$32.71	121.49% Upside

Current Analyst Ratings Breakdown

Latest TNDM, SLNO, TMDX, and INSP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/15/2025	INSP Inspire Medical Systems	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$200.00 ➝ $182.00
7/15/2025	TMDX TransMedics Group	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$129.00 ➝ $142.00
7/11/2025	SLNO Soleno Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$105.00 ➝ $121.00
7/9/2025	TNDM Tandem Diabetes Care	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Sell	$24.00 ➝ $14.00
6/23/2025	SLNO Soleno Therapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
6/23/2025	SLNO Soleno Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$110.00
6/17/2025	TMDX TransMedics Group	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$130.00 ➝ $150.00
6/17/2025	TMDX TransMedics Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/16/2025	TNDM Tandem Diabetes Care	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$24.00
6/4/2025	TMDX TransMedics Group	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$125.00 ➝ $145.00
6/3/2025	TMDX TransMedics Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INSP Inspire Medical Systems	$802.80M	4.66	$1.70 per share	74.62	$23.01 per share	5.52
SLNO Soleno Therapeutics	N/A	N/A	N/A	N/A	$5.68 per share	N/A
TMDX TransMedics Group	$441.54M	8.42	$1.60 per share	68.87	$6.81 per share	16.14
TNDM Tandem Diabetes Care	$940.20M	1.05	N/A	N/A	$4.01 per share	3.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INSP Inspire Medical Systems	$53.51M	$2.17	58.50	39.42	1.95	7.92%	10.00%	8.68%	8/5/2025 (Estimated)
SLNO Soleno Therapeutics	-$175.85M	-$4.62	N/A	N/A	N/A	N/A	-77.52%	-63.44%	8/6/2025 (Estimated)
TMDX TransMedics Group	$35.46M	$1.36	80.79	76.84	N/A	10.03%	21.88%	6.15%	7/30/2025 (Estimated)
TNDM Tandem Diabetes Care	-$96.03M	-$2.78	N/A	N/A	N/A	-18.71%	-57.33%	-13.48%	8/6/2025 (Confirmed)

Latest TNDM, SLNO, TMDX, and INSP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	SLNO Soleno Therapeutics	-$0.85	N/A	N/A	N/A	$3.91 million	N/A
8/6/2025	Q2 2025	TNDM Tandem Diabetes Care	-$0.40	N/A	N/A	N/A	$238.39 million	N/A
8/5/2025	Q2 2025	INSP Inspire Medical Systems	$0.22	N/A	N/A	N/A	$214.50 million	N/A
7/30/2025	Q2 2025	TMDX TransMedics Group	$0.48	N/A	N/A	N/A	$146.64 million	N/A
5/8/2025	Q1 2025	TMDX TransMedics Group	$0.29	$0.70	+$0.41	$0.70	$123.39 million	$143.54 million
5/7/2025	Q1 2025	SLNO Soleno Therapeutics	-$1.14	-$0.95	+$0.19	-$0.95	N/A	N/A
5/5/2025	Q1 2025	INSP Inspire Medical Systems	-$0.23	$0.10	+$0.33	$0.10	$194.89 million	$201.32 million
4/30/2025	Q1 2025	TNDM Tandem Diabetes Care	-$0.60	-$0.67	-$0.07	-$1.97	$220.19 million	$234.42 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
INSP Inspire Medical Systems	N/A	N/A	N/A	N/A	N/A
SLNO Soleno Therapeutics	N/A	N/A	N/A	N/A	N/A
TMDX TransMedics Group	N/A	N/A	N/A	N/A	N/A
TNDM Tandem Diabetes Care	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INSP Inspire Medical Systems	N/A	9.01	7.44
SLNO Soleno Therapeutics	0.21	19.64	19.64
TMDX TransMedics Group	1.92	9.10	8.32
TNDM Tandem Diabetes Care	1.99	2.30	1.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INSP Inspire Medical Systems	94.91%
SLNO Soleno Therapeutics	97.42%
TMDX TransMedics Group	99.67%
TNDM Tandem Diabetes Care	N/A

Insider Ownership

Company	Insider Ownership
INSP Inspire Medical Systems	4.10%
SLNO Soleno Therapeutics	6.40%
TMDX TransMedics Group	7.00%
TNDM Tandem Diabetes Care	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INSP Inspire Medical Systems	1,246	29.49 million	28.29 million	Optionable
SLNO Soleno Therapeutics	30	50.39 million	47.17 million	Optionable
TMDX TransMedics Group	210	33.82 million	31.46 million	Optionable
TNDM Tandem Diabetes Care	2,650	66.61 million	65.34 million	Optionable

TNDM, SLNO, TMDX, and INSP Headlines

Recent News About These Companies

FY2025 Earnings Estimate for TNDM Issued By Leerink Partnrs

July 18 at 3:01 AM | americanbankingnews.com

Tandem Diabetes Care's SWOT analysis: stock faces headwinds amid market shifts

July 17 at 10:55 PM | investing.com

What is Leerink Partnrs' Estimate for TNDM FY2025 Earnings?

July 16 at 6:46 AM | marketbeat.com

Tandem Diabetes Care (NASDAQ:TNDM) Hits New 52-Week Low - Here's What Happened

July 15 at 2:44 PM | marketbeat.com

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Bought by Stephens Investment Management Group LLC

July 13, 2025 | marketbeat.com

Earnings Forecast & History for Tandem Diabetes Care Inc (TNDM) | Price ...

July 12, 2025 | investing.com

Citigroup Reaffirms Sell Rating for Tandem Diabetes Care (NASDAQ:TNDM)

July 11, 2025 | americanbankingnews.com

Tandem Diabetes stock falls after Citi downgrades to Sell on competition concerns

July 9, 2025 | au.investing.com

Citi adjusts MedTech outlook: Bullish on Haemonetics, bearish on Tandem Diabetes

July 9, 2025 | finance.yahoo.com

Tandem Diabetes Shares Drop Following Citi Downgrade Over Rising Competition

July 9, 2025 | msn.com

Why Tandem Diabetes (TNDM) Shares Are Sliding Today

July 9, 2025 | msn.com

Tandem Diabetes Care (NASDAQ:TNDM) Sets New 12-Month Low - Here's Why

July 9, 2025 | marketbeat.com

Tandem Diabetes Care (NASDAQ:TNDM) Given "Sell" Rating at Citigroup

July 9, 2025 | marketbeat.com

Further weakness as Tandem Diabetes Care (NASDAQ:TNDM) drops 10.0% this week, taking five-year losses to 83%

July 7, 2025 | finance.yahoo.com

Mirae Asset Global Investments Co. Ltd. Sells 265,554 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

July 6, 2025 | marketbeat.com

Tandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025 - Morningstar

July 2, 2025 | morningstar.comM

RSI Alert: Tandem Diabetes Care (TNDM) Now Oversold

July 2, 2025 | nasdaq.com

TNDM - Tandem Diabetes Care Inc Key Metrics - Morningstar

July 1, 2025 | morningstar.comM

Tandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025

July 1, 2025 | businesswire.com

Tandem Diabetes Care (NASDAQ:TNDM) Shares Gap Down - Here's Why

July 1, 2025 | marketbeat.com

TNDM - Tandem Diabetes Care Inc Financials - Morningstar

June 27, 2025 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNDM, SLNO, TMDX, and INSP Company Descriptions

Inspire Medical Systems NYSE:INSP

$126.94 -1.03 (-0.80%)

Closing price 03:59 PM Eastern

Extended Trading

$127.57 +0.63 (+0.49%)

As of 06:16 PM Eastern

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.

Soleno Therapeutics NASDAQ:SLNO

$87.20 -0.44 (-0.50%)

Closing price 04:00 PM Eastern

Extended Trading

$87.16 -0.05 (-0.05%)

As of 04:32 PM Eastern

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

TransMedics Group NASDAQ:TMDX

$109.88 -2.64 (-2.35%)

Closing price 04:00 PM Eastern

Extended Trading

$110.46 +0.59 (+0.53%)

As of 07:04 PM Eastern

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Tandem Diabetes Care NASDAQ:TNDM

$14.77 -0.59 (-3.84%)

Closing price 04:00 PM Eastern

Extended Trading

$14.78 +0.01 (+0.07%)

As of 07:02 PM Eastern

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time